Mathias Krockenberger,
Yvonne Dombrowski,
Claudia Weidler,
Monika Ossadnik,
Arnd Hönig,
Sebastian Häusler,
Heike Voigt,
Jürgen C Becker,
Lin Leng,
Alexander Steinle,
Michael Weller, Richard Bucala,
Johannes Dietl,
Jörg Wischhusen
[show abstract]
[hide abstract]
ABSTRACT: The proinflammatory cytokine macrophage migration inhibitory factor (MIF) stimulates tumor cell proliferation, migration, and metastasis; promotes tumor angiogenesis; suppresses p53-mediated apoptosis; and inhibits antitumor immunity by largely unknown mechanisms. We here describe an overexpression of MIF in ovarian cancer that correlates with malignancy and the presence of ascites. Functionally, we find that MIF may contribute to the immune escape of ovarian carcinoma by transcriptionally down-regulating NKG2D in vitro and in vivo which impairs NK cell cytotoxicity toward tumor cells. Together with the additional tumorigenic properties of MIF, this finding provides a rationale for novel small-molecule inhibitors of MIF to be used for the treatment of MIF-secreting cancers.
The Journal of Immunology 07/2008; 180(11):7338-48. · 5.79 Impact Factor
